Agios sells TIBSOVO royalty rights to Sagard for $131.8M upfront

AGIOS PHARMACEUTICALS, INC.

Upfront cash payment of $131.8M for 5% royalty on U.S. net sales of TIBSOVO (ivosidenib).
Agios retains $200M milestone for vorasidenib and 15% royalties on its U.S. net sales.
Deal provides non-dilutive capital to fund PYRUKYND launch and ongoing pipeline programs.
Transaction closed on October 27, 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AGIOS PHARMACEUTICALS, INC. entered into Purchase and Sale Agreement with Sagard Healthcare Royalty Partners, LP, Sagard Healthcare Partners Co-Invest Designated Activity Company valued at $131,783,241 (effective 2022-10-27).

Action: entry
Agreement: asset purchase
Counterparty: Sagard Healthcare Royalty Partners, LP, Sagard Healthcare Partners Co-Invest Designated Activity Company
Value: $131,783,241
Effective: 2022-10-27

Exact text from the filing

On October 27, 2022, Agios Pharmaceuticals, Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempt limited partnership, and Sagard Healthcare Partners Co-Invest Designated Activity Company, a company incorporated in Ireland, as purchasers (together, the “Purchasers”), and Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempt limited partnership, as the Purchaser’s representative.

View on SEC.gov

23 material agreements filed in the last 30 days. Browse all material agreements →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-270979

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.